Limited expression of cancer-testis antigens in renal cell carcinoma patients

Soga,Norihito; Hori,Yasuhide; Yamakado,Koichiro; Ikeda,Hiroaki; Imai,Naoko; Kageyama,Shinichi; Nakase,Kazunori; Yuta,Atsushi; Hayashi,Norio; Shiku,Hiroshi; Sugimura,Yoshiki

doi:10.3892/mco.2012.40

Limited expression of cancer-testis antigens in renal cell carcinoma patients

Authors:
- Norihito Soga
- Yasuhide Hori
- Koichiro Yamakado
- Hiroaki Ikeda
- Naoko Imai
- Shinichi Kageyama
- Kazunori Nakase
- Atsushi Yuta
- Norio Hayashi
- Hiroshi Shiku
- Yoshiki Sugimura
View Affiliations

Affiliations: Division of Urology, Aichi Cancer Center Hospital, Nagoya, Aichi 464-8681, Japan, Division of Nephro-Urologic Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan, Division of Radiology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan, Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan, Department of Cancer Center, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan, Department of Otorhinolaryngology, Head and Neck Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
Published online on: November 19, 2012 https://doi.org/10.3892/mco.2012.40
Pages: 326-330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the frequency of expression of the cancer-testis antigens (CTAs) NY‑ESO‑1, MAGE‑A4 and SAGE, in renal cell carcinoma (RCC) patients compared to that in head and neck cancer (HNC) patients, which represent a positive control with a high incidence of CTA expression, to identify novel target antigens for immunotherapy. We prospectively examined frozen tissue samples collected from surgery or biopsy from 35 RCC and 40 HNC patients. Total RNA was extracted, and real‑time reverse transcription‑polymerase chain reaction (RT)-PCR was performed to determine the expression of MAGE‑A4, NY‑ESO‑1 and SAGE. MAGE‑A4 was not detected in any of the RCC samples, although a low incidence of NY‑ESO‑1 (5.7%; 2/35) and SAGE (2.9%; 1/35) expression was observed. No samples demonstrated co‑expression of the three CTAs. By contrast, a comparatively high incidence of CTA expression was detected in squamous cell carcinoma (SCC) specimens of HNC patients. The actual incidence was 42.5% (17/40) for MAGE‑A4, 20% (8/40) for NY‑ESO‑1 and 15% (6/40) for SAGE. The incidence of co-expression was 7.5% (3/40) for MAGE‑A4 and NY‑ESO‑1, 7.5% (3/40) for MAGE‑A4 and SAGE, 7.5% (3/40) for NY‑ESO‑1 and SAGE, and 2.5% (1/40) for the CTAs. The number of HNC samples positive for MAGE‑A4 was significantly higher compared to that of RCC samples. The remaining two antigens, NY‑ESO‑1 and SAGE, were expressed at high levels in HNC compared to RCC samples. Limited frequency of CTA (NY‑ESO‑1, MAGE‑A4 and SAGE) expression was demonstrated in RCC compared to HNC samples.

View Figures

View References

1	Hofmann HS, Neef H, Krohe K, Andreev P and Silber RE: Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 48:77–82. 2005. View Article : Google Scholar : PubMed/NCBI
2	Levy DA, Slaton JW, Swanson DA and Dinney CP: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 159:1163–1167. 1998. View Article : Google Scholar : PubMed/NCBI
3	Ljungberg B, Alamdari FI, Rasmuson T and Roos G: Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 84:405–411. 1999. View Article : Google Scholar : PubMed/NCBI
4	Pyrhönen S, Salminen E, Ruutu M, et al: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 17:2859–2867. 1999.PubMed/NCBI
5	Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar
6	Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
7	Shimizu K, Uemura H, Yoshikawa M, et al: Induction of antigen-specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma. Oncol Rep. 10:1307–1311. 2003.PubMed/NCBI
8	Sato E, Torigoe T, Hirohashi Y, et al: Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res. 14:6916–6923. 2008. View Article : Google Scholar : PubMed/NCBI
9	Boon T and Old LJ: Cancer tumor antigens. Curr Opin Immunol. 9:681–683. 1997. View Article : Google Scholar
10	Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
11	Uyttenhove C, Godfraind C, Lethé B, et al: The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 70:349–356. 1997. View Article : Google Scholar : PubMed/NCBI
12	Jungbluth AA, Chen YT, Stockert E, et al: Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 92:856–860. 2001. View Article : Google Scholar : PubMed/NCBI
13	De Plaen E, Arden K, Traversari C, et al: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 40:360–369. 1994.PubMed/NCBI
14	Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T and Lucas S: An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61:5544–5551. 2001.PubMed/NCBI
15	Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
16	Chen YT, Chiu R, Lee P, et al: Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. Hum Reprod. 26:3232–3243. 2011. View Article : Google Scholar : PubMed/NCBI
17	Aoki M, Ueda S, Nishikawa H, et al: Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine. 27:6854–6861. 2009. View Article : Google Scholar : PubMed/NCBI
18	Shirakura Y, Mizuno Y, Wang L, et al: T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice. Cancer Sci. 103:17–25. 2012.PubMed/NCBI
19	Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S and Kamidono S: Expression of MAGE genes in renal cell carcinoma. Int J Mol Med. 2:57–60. 1998.PubMed/NCBI
20	Neumann E, Engelsberg A, Decker J, et al: Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res. 58:4090–4095. 1998.
21	Jungbluth AA, Busam KJ, Kolb D, et al: Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer. 85:460–465. 2000. View Article : Google Scholar : PubMed/NCBI
22	Coral S, Sigalotti L, Altomonte M, et al: 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res. 8:2690–2695. 2002.
23	Kienstra MA, Neel HB, Strome SE and Roche P: Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck. 25:457–463. 2003. View Article : Google Scholar : PubMed/NCBI
24	Scanlan MJ, Altorki NK, Gure AO, et al: Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett. 150:155–164. 2000. View Article : Google Scholar : PubMed/NCBI
25	Figueiredo DL, Mamede RC, Spagnoli GC, et al: High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck. 33:702–707. 2010. View Article : Google Scholar : PubMed/NCBI
26	Pastorcic-Grgic M, Sarcevic B, Dosen D, Juretic A, Spagnoli GC and Grgic M: Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer. Head Neck. 32:1178–1184. 2010. View Article : Google Scholar : PubMed/NCBI
27	Cuffel C, Rivals JP, Zaugg Y, et al: Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer. 128:2625–2634. 2010. View Article : Google Scholar : PubMed/NCBI
28	Atanackovic D, Blum I, Cao Y, et al: Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther. 5:1218–1225. 2006. View Article : Google Scholar : PubMed/NCBI
29	De Smet C, Lurquin C, Lethe B, Martelange V and Boon T: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol. 19:7327–7335. 1999.PubMed/NCBI
30	Demirovic A, Dzombeta T, Tomas D, et al: Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma. Pathol Res Pract. 206:695–699. 2010. View Article : Google Scholar : PubMed/NCBI